Thyroid Hormone Receptor-β Agonists: Titration & Tapering Algorithms

What Is the THR-β Agonist Drug Class?

THR-β agonists are liver-selective thyromimetics that activate the thyroid hormone receptor beta isoform preferentially over the alpha isoform. This selectivity concentrates metabolic effects in hepatocytes while largely sparing cardiac and bone tissue from thyrotoxic harm. The class was designed to exploit the liver's heavy expression of THR-β to reduce hepatic lipogenesis, increase mitochondrial fatty acid oxidation, and suppress VLDL secretion.

Resmetirom is the only approved member. It is a nonsteroidal small molecule with a half-life of approximately 4 to 5 hours and undergoes extensive first-pass hepatic uptake, which accounts for most of its tissue selectivity. FDA prescribing information confirms hepatic concentrations roughly 300-fold above plasma [1].

Mechanism at the Receptor Level

THR-β sits in the nucleus and, when activated, drives transcription of genes controlling lipid catabolism. Resmetirom binding upregulates mitochondrial uncoupling, increases LDL receptor expression, and reduces apolipoprotein CIII production. The net hepatic effect mirrors euthyroid-to-hyperthyroid metabolic shifts without meaningfully raising heart rate or accelerating bone turnover.

Why Selectivity Matters for MASH

MASH (metabolic dysfunction-associated steatohepatitis) is driven substantially by hepatic lipid overload. A thyromimetic that targets the liver preferentially can reduce steatosis and the downstream inflammatory cascade without producing the tachycardia or atrial fibrillation risk that non-selective thyroid agonists carry. A 2023 review in the New England Journal of Medicine described MASH fibrosis as the primary determinant of liver-related mortality, framing THR-β agonism as mechanistically well-matched to the condition [2].

FDA Approval and the MAESTRO-NASH Trial

The FDA granted resmetirom approval on March 14, 2024, based primarily on MAESTRO-NASH, a phase 3 randomized controlled trial enrolling 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3.

Primary Endpoints and Outcomes

MAESTRO-NASH used a co-primary histologic endpoint design. At 52 weeks:

• MASH resolution without worsening fibrosis occurred in 25.9% of patients receiving resmetirom 80 mg versus 9.7% on placebo (P<0.001) [3].
• MASH resolution without worsening fibrosis occurred in 29.9% of patients receiving resmetirom 100 mg versus the same 9.7% placebo arm (P<0.001) [3].
• Fibrosis improvement by at least one stage without MASH worsening was achieved in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo [3].

These findings were published in the New England Journal of Medicine in 2024 and formed the core of the FDA submission [3].

Secondary Lipid Findings

LDL-C fell by approximately 13 to 16% from baseline in the resmetirom arms at 24 weeks, a finding consistent with the drug's mechanism of upregulating hepatic LDL receptor expression. Triglycerides fell by roughly 17 to 19%. These lipid shifts are clinically relevant when planning statin coadministration and when anticipating rebound after discontinuation.

Titration Algorithm: Weight-Based, Not Time-Based

The titration framework for resmetirom differs from most metabolic drugs in that dose selection is determined by body weight at treatment initiation, not by a step-up schedule over weeks.

Starting Dose Selection

| Body Weight at Baseline | Recommended Dose | |---|---| | <100 kg | 80 mg orally once daily | | ≥100 kg | 100 mg orally once daily |

The drug is taken with food to maximize absorption; fasting-state AUC is approximately 30% lower [1]. There is no half-dose induction period in the approved label. Patients begin at their full weight-based dose on day one.

Dose Modification for CYP2C8 Inhibitors

Strong CYP2C8 inhibitors (gemfibrozil is the most clinically frequent example in a dyslipidemia-MASH population) can raise resmetirom plasma exposure substantially. The label specifies reducing resmetirom to 80 mg once daily regardless of body weight when a strong CYP2C8 inhibitor is coadministered [1]. Moderate CYP2C8 inhibitors (trimethoprim, deferasirox) warrant monitoring but do not mandate a fixed dose reduction per current labeling.

Hepatic Impairment Adjustments

Resmetirom is contraindicated in patients with decompensated cirrhosis. In the MAESTRO-NASH trial, Child-Pugh A patients (compensated cirrhosis) were excluded from the primary analysis. The approved indication explicitly covers F2-F3 fibrosis only. Prescribers should confirm fibrosis stage by biopsy or validated noninvasive testing (FIB-4 index ≥1.30 with confirmatory elastography) before initiating. There is no dose reduction requirement for mild or moderate hepatic impairment, but exposure may change as fibrosis stage improves over therapy.

Proposed HealthRX Monitoring Framework at Each Titration Decision Point

Below is the decision logic our medical team applies at each clinical touchpoint for a patient starting resmetirom. This framework synthesizes the FDA label, MAESTRO-NASH protocol, and current AASLD guidance on MASH management [4].

Baseline (before dose 1):

• Confirm fibrosis stage F2 or F3 by biopsy or FIB-4 plus elastography.
• Record body weight (determines 80 mg vs. 100 mg).
• Obtain LFTs, total bilirubin, INR, CBC.
• Review drug list for CYP2C8 inhibitors and P-gp substrates (digoxin, colchicine, resmetirom is a P-gp inhibitor).
• Screen for biliary pathology; active biliary obstruction is a contraindication.

Week 4:

• Recheck AST, ALT, alkaline phosphatase, total bilirubin.
• If ALT rises more than three times baseline or total bilirubin doubles, hold and evaluate for drug-induced liver injury versus disease flare.
• Record body weight; if patient has crossed the 100 kg threshold after starting at 80 mg, clinical judgment guides dose adjustment (the label does not mandate up-titration post-initiation).

Week 12:

• Fasting lipid panel to assess LDL-C and triglyceride response.
• If LDL-C has not fallen at all, confirm adherence and check for new CYP2C8 inducers.
• Assess for biliary symptoms (right upper quadrant discomfort, jaundice, acholic stools).

Week 24 and every 24 weeks thereafter:

• Repeat LFTs.
• Noninvasive fibrosis reassessment at 52 weeks (elastography or FIB-4) to gauge histologic trajectory.
• Patient-reported tolerability, particularly GI symptoms (nausea, diarrhea occurred in roughly 9 to 16% of MAESTRO-NASH participants) [3].

Tapering Algorithm: When and How to Discontinue

No pharmacokinetic rationale exists for a mandatory taper of resmetirom. The drug has a short half-life (4 to 5 hours) and does not suppress the hypothalamic-pituitary-thyroid axis, because its action is peripheral and liver-directed. Abrupt discontinuation does not cause a withdrawal syndrome analogous to exogenous thyroid hormone cessation.

Routine Discontinuation

When stopping resmetirom for reasons other than toxicity (insurance coverage loss, patient preference, planned pregnancy), the practical concern is lipid rebound. LDL-C returns toward baseline within four to eight weeks of stopping. Prescribers should:

1. Check a fasting lipid panel four weeks after the last dose.
2. Adjust background statin or ezetimibe dosing preemptively if the patient's cardiovascular risk category warrants LDL-C <70 mg/dL.
3. Document the reason for discontinuation in the chart, as MASH fibrosis may progress without treatment.

Discontinuation for Hepatotoxicity

If ALT or AST exceeds five times the upper limit of normal, or if jaundice develops, resmetirom should be stopped immediately and not restarted without subspecialty hepatology review. The MAESTRO-NASH trial reported serious hepatic adverse events in fewer than 2% of participants, but the threshold for stopping is lower in real-world patients who may have comorbid alcohol use or drug-drug interactions not represented in the trial [3].

Discontinuation Before Invasive Procedures

No preoperative taper is required. Because resmetirom does not alter coagulation pathways directly and clears within 24 hours at steady-state half-life calculations, standard perioperative management applies. The exception is patients also taking warfarin: resmetirom inhibits CYP2C9 and may raise INR. Holding resmetirom two to three days before elective surgery in anticoagulated patients is a reasonable precaution, though the label does not formally address this scenario.

Drug-Drug Interactions Relevant to Titration Decisions

Understanding interactions is not merely a safety box to check. Several interactions directly affect whether a dose adjustment is needed.

Statin Interactions

Resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters. This raises plasma concentrations of statins that rely on these transporters, particularly rosuvastatin and pitavastatin. The label recommends a rosuvastatin dose cap of 20 mg/day and a pitavastatin cap of 2 mg/day when coadministered with resmetirom [1]. Failure to cap statin doses risks myopathy, which can confuse the clinical picture in a patient already monitored for hepatic enzyme elevations.

Digoxin and P-gp Substrates

Resmetirom inhibits P-glycoprotein. Digoxin toxicity has been reported with P-gp inhibitors even at therapeutic digoxin doses. Check digoxin levels two weeks after starting resmetirom and again at week eight. No dose adjustment is built into the resmetirom label, but digoxin dose reduction may be necessary based on trough levels [1].

Oral Contraceptives and Hormone-Based Therapies

Resmetirom does not meaningfully inhibit CYP3A4, so combined oral contraceptives are not expected to have altered efficacy. Patients using thyroid hormone replacement (levothyroxine) for hypothyroidism may see shifts in TSH because resmetirom's peripheral mechanism does not alter circulating T3 or T4, but hepatic metabolism of thyroid hormones may shift modestly. Recheck TSH at week 12 in patients on stable levothyroxine doses.

Patient Selection: Who Gets 80 mg vs. 100 mg

The binary weight-based dosing makes patient selection straightforward in principle but raises practical questions at the clinical boundary.

The 95 to 105 kg Zone

A patient weighing 97 kg starts at 80 mg. If they gain weight to 103 kg by week 12, the label does not require escalating to 100 mg post-initiation, because dose assignment occurs at baseline. Some prescribers elect to escalate in this scenario, reasoning that the 100 mg arm showed numerically higher MASH resolution rates in MAESTRO-NASH (29.9% vs. 25.9%) [3]. That decision requires shared decision-making and documentation of the off-label rationale.

Patients with F1B Fibrosis

MAESTRO-NASH enrolled some F1B patients, but the approved indication covers F2 and F3 only. Prescribing resmetirom for F1B MASH is off-label. The American Association for the Study of Liver Diseases 2023 MASH guidance does not yet recommend pharmacotherapy for F1 fibrosis, given that the fibrosis-related mortality risk is lower [4]. Starting resmetirom in F1B requires documentation of a compelling clinical rationale (rapidly rising FIB-4, concurrent metabolic syndrome with high cardiovascular risk).

Patients Already on GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, tirzepatide) are being studied in MASH concurrently. As of early 2025, no head-to-head data compare GLP-1 monotherapy versus resmetirom monotherapy for histologic endpoints. Combination use is not addressed in the resmetirom label and was not part of MAESTRO-NASH. The practical guidance is to establish a stable GLP-1 dose before adding resmetirom, then monitor for additive GI side effects (nausea, diarrhea) during the first four weeks.

Monitoring for Thyromimetic Off-Target Effects

Because resmetirom activates THR-β preferentially, cardiac and bone effects are attenuated relative to full thyroid hormone agonism. MAESTRO-NASH showed no significant increase in atrial fibrillation, tachycardia, or bone mineral density loss at 52 weeks [3]. Still, several monitoring points apply.

Cardiac Monitoring

In the 52-week MAESTRO-NASH dataset, mean heart rate change from baseline was less than one beat per minute in both resmetirom arms. An electrocardiogram at baseline is warranted only if the patient has known cardiac arrhythmia or is on antiarrhythmic drugs. Routine cardiac monitoring beyond standard MASH care is not required by the label [1].

Bone Density

No mandatory DEXA scan is included in the resmetirom label. Longer-duration safety data beyond 52 weeks are being collected in the ongoing MAESTRO-NASH outcomes trial. Prescribers managing postmenopausal women with existing osteopenia may choose annual DEXA surveillance, though this is a clinical judgment call rather than a label requirement.

Thyroid Function Tests

TSH does not change with resmetirom in euthyroid patients, because the drug does not alter the hypothalamic-pituitary axis. A pharmacodynamic analysis published via NIH confirmed stable TSH, T3, and T4 levels across 52 weeks in MAESTRO-NASH participants [5]. Routine TSH monitoring is not indicated unless the patient has known thyroid disease or is on levothyroxine (in which case check at week 12 as noted above).

Special Populations

Pregnancy and Lactation

Resmetirom is not recommended during pregnancy. Animal reproductive studies showed fetal harm at doses approximating human exposure. Women of childbearing potential should use effective contraception. There are no human lactation data. Given the drug's hepatic concentration mechanism and molecular size, excretion into breast milk cannot be excluded, and breastfeeding is not advised during treatment [1].

Older Adults (Age ≥65)

MAESTRO-NASH included patients up to age 75. No age-specific dose adjustment is required, but polypharmacy risk is higher in older patients. The P-gp inhibition interaction with digoxin and the statin cap requirements are especially relevant in this group.

Renal Impairment

Resmetirom undergoes minimal renal elimination. No dose adjustment is required for any degree of renal impairment, including end-stage renal disease [1].

The Broader THR-β Pipeline

Resmetirom is the class prototype, but it will not be the only member. As of early 2025, at least two additional THR-β agonists are in phase 2 development for MASH and for conditions including NASH-related dyslipidemia and non-alcoholic fatty liver disease overlapping with type 2 diabetes. The titration frameworks being developed for those agents will likely share the weight-based or exposure-based logic established by resmetirom, though each will carry its own half-life and isoform-selectivity profile that may alter the monitoring intervals.

The FDA guidance on drug development for NASH/MASH endpoints outlines acceptable histologic and noninvasive surrogate endpoints that next-generation THR-β agonists will need to satisfy [6]. Prescribers adopting resmetirom now are effectively building the clinical infrastructure for managing this class as it expands.